Skip to content
Subscriber Only

Pfizer to Braid Old Blockbusters Into Mylan, Reshaping Industry

  • Pact will focus Pfizer on innovation, beef up struggling Mylan
  • Mylan shares, bonds surge as drugmaker’s financial clouds part
Video player cover image
Bloomberg Intelligence’s Sam Fazeli examine’s Pfizer combining a unit with Mylan.Daybreak: Americas." (Source: Bloomberg)
Updated on

Pfizer Inc. plans to combine its business that sells older blockbuster medicines such as Lipitor and Viagra with generic drugmaker Mylan NV, in a deal that will reshape the brand-name and off-patent pharmaceutical industries.

Under the terms of the all-stock transaction, Mylan investors would get 43% of the new entity and Pfizer investors the rest. The new publicly traded company will have sales of about $19 billion to $20 billion in 2020, the drugmakers said in a statement.